Lamivudina Aurobindo (Lamivudine)

Lamivudine is a nucleoside analogue that, after intracellular phosphorylation, mimics natural nucleotides. The active triphosphate competes with deoxycytidine triphosphate for incorporation by HIV reverse transcriptase, causing premature DNA chain termination and thereby blocking viral replication.

The dosage of lamivudine is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and the specific indication. Healthcare providers determine the appropriate strength and frequency according to current clinical guidelines.

Safety data for lamivudine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other NRTIs or drugs from different classes for optimal viral suppression. Compared with older NRTIs, lamivudine generally has a favorable safety profile, lower mitochondrial toxicity, and fewer drug‑interaction concerns, making it a common component of modern combination regimens.

Lamivudina Aurobindo should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain product stability throughout its shelf life.

Lamivudine is taken orally, usually as a tablet, with or without food. The exact dosing schedule—once daily or twice daily—depends on the prescribing clinician’s assessment and the therapeutic regimen selected for the patient.

Serious adverse events, though rare, include lactic acidosis, severe liver injury, pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with pre‑existing severe liver disease, mitochondrial disorders, or those receiving contraindicated medications such as didanosine or stavudine.